Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

299,544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trial.
Coleman RL, Lorusso D, Oaknin A, Cecere SC, Denys H, Colombo N, van Gorp T, Konner JA, Romeo Marin M, Harter P, Murphy C, Wang Y, Esteves B, Method M, Matulonis U. Coleman RL, et al. Among authors: wang y. Int J Gynecol Cancer. 2024 Aug 5;34(8):1119-1125. doi: 10.1136/ijgc-2024-005401. Int J Gynecol Cancer. 2024. PMID: 38858103 Free PMC article. Clinical Trial.
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. Among authors: wang y. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Richardson DL, Moore KN, Vergote I, Gilbert L, Martin LP, Mantia-Smaldone GM, Castro CM, Provencher D, Matulonis UA, Stec J, Wang Y, Method M, O'Malley DM. Richardson DL, et al. Among authors: wang y. Gynecol Oncol. 2024 Jun;185:186-193. doi: 10.1016/j.ygyno.2024.01.045. Epub 2024 Mar 5. Gynecol Oncol. 2024. PMID: 38447347 Free article. Clinical Trial.
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Moore KN, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, O'Malley DM, Banerjee S, Murphy CG, Harter P, Konecny GE, Pautier P, Method M, Wang Y, Coleman RL, Birrer M, Matulonis UA. Moore KN, et al. Among authors: wang y. Gynecol Oncol. 2024 Dec;191:249-258. doi: 10.1016/j.ygyno.2024.10.013. Epub 2024 Oct 25. Gynecol Oncol. 2024. PMID: 39461270
Mina53 catalyzes arginine demethylation of p53 to promote tumor growth.
Zhou L, Yu L, Song S, Wang Y, Zhu Q, Li M, Sha Y, Xu L, Shu X, Liao Q, Wu T, Yang B, Chai S, Lin B, Wu L, Zhou R, Duan X, Zhu C, Ruan Y, Yi W. Zhou L, et al. Among authors: wang y. Cell Rep. 2025 Jan 25;44(2):115242. doi: 10.1016/j.celrep.2025.115242. Online ahead of print. Cell Rep. 2025. PMID: 39864061
Evolutionary dynamics of SARS-CoV-2 variants under strict non-pharmaceutical interventions - a population-based study.
Huo X, Cui L, Zhu L, Zhang J, Fan H, Yi Y, Zhao J, Ge Y, Wang S, Han X, Gao X, Qi X, Fu J, Li Z, Fan H, Yu H, Deng F, Zhao K, Zhu X, Hu J, Li J, Ai J, Kang G, Shen Y, Jin G, Wang F, Zhang Z, He M, Ding S, Wang Y, Dong Y, Huang Y, Yi C, Wang L, Jiao Y, Wang J, Li J, Liu H, Li J, Bao C, Wu M, Zhu F. Huo X, et al. Among authors: wang y. J Infect Dev Ctries. 2024 Dec 31;18(12.1):S214-S226. doi: 10.3855/jidc.19409. J Infect Dev Ctries. 2024. PMID: 39863937
299,544 results
You have reached the last available page of results. Please see the User Guide for more information.